Amphetamines

14 PRODUCTS · CLASS OVERVIEW

Reviewed by Tariq Halim, MD · Last medical review: November 12, 2026 · Editorial policy

This page lists the 14 amphetamine products on this site, with the facts each product page cites from its FDA label. Open a product for full details, both patient and clinician views, and sources.

Overview

How it works

Schematic of amphetamine mechanism: DAT and NET reversal with increased dopamine and norepinephrine release
Schematic: amphetamine reduces reuptake through DAT and NET and promotes release of dopamine and norepinephrine (transporter reversal). The VMAT2 (vesicular) step shown reflects general pharmacology literature rather than FDA labeling.

Amphetamine increases the amount of dopamine and norepinephrine available between nerve cells, both by blocking their reuptake and by promoting their release. This supports attention and impulse control.

Mechanism summary reused from the Adderall page (mechanism per its Prescribing Information, revised 05/2024).

Products

Formulation, duration and approved ages as stated on each product page (from its label). Generic: “Yes” means an FDA-approved generic or authorized generic is available.

ProductFormulationDurationApproved agesGeneric
VyvanseCapsule; chewable tabletBenefit through 12–13 hours in children and up to 14 hours in adults in label studies.ADHD: 6 years and older; BED: adultsYes
Adderall XRExtended-release capsuleOnce daily on awakening; the label gives no duration in hours (morning and afternoon benefit in studies; peak about 7 hours).6 years and older (children, adolescents, adults)Yes
XelstrymTransdermal systemPatch worn up to 9 hours; scores averaged across 1 to 12 hours after application beat placebo in the pediatric study.6 years and older (children, adolescents, adults)No
Adderall
shortage listed · sources differ on brand status
TabletNo fixed duration in the label; doses are given 4–6 hours apart (peak about 3 hours).ADHD: 3 years and older (not recommended under 3); also narcolepsyYes
MydayisExtended-release capsuleUp to 16 hours (label); significant from 2 or 4 hours through 16 hours in adult studies.13 years and older (adolescents and adults)Yes
Adzenys XR-ODTExtended-release orally disintegrating tabletNo fixed duration in the label; peak about 5 hours; matched doses are bioequivalent to Adderall XR.6 years and olderYes
Dyanavel XRExtended-release oral suspension; extended-release tabletBenefit at every time point from 1 to 13 hours in the label classroom study.6 years and olderNo
EvekeoTabletNo single-dose duration in the label; in a classroom study one morning dose helped from about 45 minutes through 10 hours.ADHD (3 years and older); narcolepsy; exogenous obesity (short-term adjunct, not under 12)Yes
AryntaOral solutionExpected to match Vyvanse: benefit through about 12–13 hours in children and up to 14 hours in adults in Vyvanse studies.ADHD: 6 years and older; BED: adultsNo
ZenzediTabletNo fixed duration in the label; doses are given 4–6 hours apart (peak about 3 hours).ADHD ages 3–16; narcolepsyYes
ProCentraOral solutionNo fixed duration in the label; doses are given on waking and 4–6 hours apart.ADHD ages 3–16; narcolepsyYes
Dexedrine SpansuleSustained-release capsuleThe label states no fixed duration (peak about 8 hours after a 15 mg dose).ADHD ages 6–16 (not recommended under 6); narcolepsyYes
Evekeo ODT
discontinued
Orally disintegrating tabletShort-acting; the label gives no duration (an extra dose 4 to 6 hours later if needed).6–17 yearsNo
DesoxynTabletThe label gives no duration of effect (half-life 4–5 hours).ADHD: pediatric patients 6 years and olderYes

What published studies show

These findings come from published research, not from the FDA labels. They describe groups of people; they cannot predict how one person will respond. Talk to your prescriber.

For clinicians: figures and sources
  • Efficacy: Cortese 2018 NMA (133 RCTs), clinician-rated SMD vs placebo, amphetamines −1.02 (95% CI −1.19 to −0.85) in children and −0.79 (−0.99 to −0.58) in adults; AE discontinuation OR 2.30 (children) and 3.26 (adults) (PubMed 30097390). Cochrane, children: 23 RCTs, n=2,675, CGI-I responder RR 3.36 (2.48–4.55), low to very low quality (PubMed 26844979). Cochrane, adults: 19 RCTs, n=2,521, clinician-rated SMD −0.90 (−1.04 to −0.75); AE withdrawal RR 2.69 (1.63–4.45); 16 of 19 studies industry funded (PubMed 30091808).
  • Dose: incremental benefit fell beyond 20 mg/day amphetamine in fixed-dose pediatric trials (Farhat 2022, 65 RCTs, n=7,877; PubMed 35027679); pediatric efficacy plateaued near 25 mg/day and adult near 50 mg/day (Nourredine 2026, 113 RCTs; PubMed 42134365); adults, unlicensed vs licensed amphetamine doses SMD −0.08 (−0.24 to 0.08), not FDA-approved (Farhat 2024; PubMed 37878348).
  • Switching: crossover RCT in 36 medication-naive children 9–14, favourable response 26 (72%) on each stimulant, 33 (92%) when both were tried (Ramtvedt 2013; PubMed 23659360); 41% of 49 adults switched stimulant family within 90 days for tolerability (Biederman 2021; PubMed 33657069).
  • Tics: 22 RCTs, n=2,385, new/worse tics 5.7% vs 6.5%, RR 0.99 (0.78–1.27) (Cohen 2015; PubMed 26299294); ADHD + tic disorder NMA, 8 RCTs, stimulants tics SMD −0.22 (−0.49 to 0.05), low to very low certainty (Farhat 2024; PubMed 39320340).
  • Outcomes (within-individual, observational): psychiatric hospitalization aHR 0.80 (0.78–0.82) lisdexamphetamine, 0.74 (0.61–0.90) amphetamine; suicidal behaviour 0.76 (0.68–0.84) lisdexamphetamine (Taipale 2024, n=221,714; PubMed 38506810); MVC ED visits OR 0.62 men, 0.58 women (PubMed 28492937); substance-related ED visits OR 0.65 men, 0.69 women (PubMed 28659039); convictions 32% lower in men, 41% in women (PubMed 23171097).
  • Heart (class-level): aHR 0.75 (0.31–1.85) in 1,200,438 aged 2–24 (PubMed 22043968); current vs remote use RR 1.03 (0.86–1.24) in adults (PubMed 22161946); heart failure/cardiomyopathy <50 per 10,000 person-years under 45 in 2,012,948 initiators (FDA Sentinel; PubMed 30102629).
  • Pregnancy: amphetamine/dextroamphetamine in the second half of pregnancy, autism aHR 0.80 (0.56–1.14), ADHD 1.07 (0.89–1.28) (PubMed 38265792); pooled HR any neurodevelopmental disorder 1.00 (0.83–1.20) (PubMed 40148550); preeclampsia aRR 1.29 (1.11–1.49) with early-pregnancy use and preterm birth 1.30 (1.10–1.55) with continuation (PubMed 29112657); continuation into 2nd/3rd trimester pre-eclampsia RR 1.42, preterm 1.34 (PubMed 41400021).

Each study is summarized, with its limits and funding, in the Clinical evidence section of every amphetamine and lisdexamfetamine product page.

Comparisons and guides

Sources

Each product’s current prescribing information, as cited on its page (other sources are listed on each product page):

EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. See the medical disclaimer.
Back to top